PT  - JOURNAL ARTICLE
AU  - R Alexander Speight
AU  - John C Mansfield
TI  - Drug advances in inflammatory bowel disease
AID  - 10.7861/clinmedicine.13-4-378
DP  - 2013 Aug 01
TA  - Clinical Medicine
PG  - 378--382
VI  - 13
IP  - 4
4099  - http://www.rcpjournals.org/content/13/4/378.short
4100  - http://www.rcpjournals.org/content/13/4/378.full
SO  - Clin Med2013 Aug 01; 13
AB  - The pathogenesis of inflammatory bowel disease (IBD) remains incompletely understood, but is thought to be a consequence of immune dysregulation, impaired mucosal integrity, enteric bacterial dysbiosis and genetic susceptibility factors. Recent drug advances in the treatment of IBD have clarified the role of existing medication, including 5-amino-salicylic acids (5-ASAs) and has seen a burgeoning use of treatment with biologicals. With recent advances in our understanding of these debilitating diseases, it is hoped that novel therapeutic targets can be identified.